137 related articles for article (PubMed ID: 20493436)
1. [Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO about the medical management of locally advanced or metastatic kidney cancer].
Patard JJ; Escudier B; Paparel P; Neuzillet Y; Long JA; Baumert H; Correas JM; Lang H; Poissonnier L; Rioux-Leclercq N; Soulié M;
Prog Urol; 2010 Mar; 20 Suppl 1():S11-5. PubMed ID: 20493436
[TBL] [Abstract][Full Text] [Related]
2. [The 2010 news: highlights of the ASCO-GU, UAE, ASCO, AUA congress…].
Bessede T; Bigot P; Neuzillet Y; Pignot G; Patard JJ; Pfister Ch; Rigaud J; Salomon L; Soulié M
Prog Urol; 2011 Mar; 21 Suppl 2():S16-22. PubMed ID: 21397822
[TBL] [Abstract][Full Text] [Related]
3. [What's new in 2009 about urothelial tumors? Live from EAU, AUA and ASCO, ASCO-GU].
Amsellem-Ouazana D; Theodore C; Irani J; Bernardini S; Bonnal JL; Chauvet B; Colombel M; Davin JL; Laurent G; Lebret T; Maidenberg M; Mazerolles C; Pfister C; Roupret M; Roy C; Rozet F; Saint F; Soulié M; Guillotreau J
Prog Urol; 2010 Mar; 20 Suppl 1():S38-40. PubMed ID: 20493442
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
5. Debulking nephrectomy in metastatic renal cancer.
Flanigan RC
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6335S-41S. PubMed ID: 15448027
[TBL] [Abstract][Full Text] [Related]
6. The role of radical nephrectomy in metastatic renal cell carcinoma.
Flanigan RC; Yonover PM
Semin Urol Oncol; 2001 May; 19(2):98-102. PubMed ID: 11354539
[TBL] [Abstract][Full Text] [Related]
7. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
8. [Metastatic kidney cancer: new therapeutic approaches].
Negrier S; Mejean A; Oudard S; Escudier B
Prog Urol; 2002 Sep; 12(4):703-8. PubMed ID: 12463140
[TBL] [Abstract][Full Text] [Related]
9. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
Wood CG
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Healy KA; Marshall FF; Ogan K
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
[TBL] [Abstract][Full Text] [Related]
13. Cytokine and vaccine therapy of kidney cancer.
Doehn C; Kausch I; Melz S; Behm A; Jocham D
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1097-111. PubMed ID: 15606336
[TBL] [Abstract][Full Text] [Related]
14. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
15. A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients.
Ficarra V; Galfano A; Guillé F; Schips L; Tostain J; Mejean A; Lang H; Mulders P; De La Taille A; Chautard D; Descotes JL; Cindolo L; Novara G; Rioux-Leclercq N; Zattoni F; Artibani W; Patard JJ
J Urol; 2007 Aug; 178(2):418-24; discussion 423-4. PubMed ID: 17561128
[TBL] [Abstract][Full Text] [Related]
16. Prognostic models and algorithms in renal cell carcinoma.
Lane BR; Kattan MW
Urol Clin North Am; 2008 Nov; 35(4):613-25; vii. PubMed ID: 18992615
[TBL] [Abstract][Full Text] [Related]
17. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
19. Patient-based strategy for systemic treatment of metastatic renal cell carcinoma.
Kirchner H; Strumberg D; Bahl A; Overkamp F
Expert Rev Anticancer Ther; 2010 Apr; 10(4):585-96. PubMed ID: 20397923
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.
Halbert RJ; Figlin RA; Atkins MB; Bernal M; Hutson TE; Uzzo RG; Bukowski RM; Khan KD; Wood CG; Dubois RW
Cancer; 2006 Nov; 107(10):2375-83. PubMed ID: 17048248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
